ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Feb 2021
For professionals
European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.
Topics
Children and young people
Medicines
Diet and nutrition
Biologics and newer medicines
Jargon explained
paediatric
penetrating disease
stricturing disease
exclusive enteral nutrition
anti-TNF
immunomodulator
therapeutic drug monitoring
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Aug 2026
For professionals
The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.
Topics
Children and young people
Diet and nutrition
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
therapeutic drug monitoring
exclusive enteral nutrition
endoscopic remission
NICE
Guideline
Feb 2016
For professionals
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
therapeutic drug monitoring
drug level
anti-drug antibodies
ELISA
anti-TNF
Crohn's & Colitis UK
Guide
Jun 2024
For patients
A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
infusion
subcutaneous
biosimilar
drug levels
antibodies
NHS Lothian
Web page
Dec 2020
Patients and professionals
NHS Lothian's IBD page on monitoring medicines. It explains that people on infliximab or adalimumab have their drug level checked some weeks after starting and then at least yearly, with anti-drug antibodies tested if the level is low.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
drug level
anti-drug antibodies
anti-TNF
shared care
Frontline Gastroenterology (via PMC)
Guide
Nov 2025
For professionals
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics
Medicines
Surgery
Monitoring
Jargon explained
top-down
step-up
therapeutic drug monitoring
ileocaecal resection
Rutgeerts score
immunogenicity
Crohn's & Colitis UK
Guide
Sep 2024
For patients
A guide to adalimumab, an anti-TNF biologic you inject under your skin with a pen or syringe. It explains that Humira was the first brand and Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma are biosimilars, and that blood tests may check drug and antibody levels.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
biosimilar
antibodies
subcutaneous injection
The Lancet
Study
Feb 2015
For professionals
A trial of how to stop Crohn's returning after bowel surgery. Treating people according to their risk, checking with a colonoscopy at six months and stepping up treatment if the disease had come back worked better than standard drug treatment alone. It also showed that even low-risk patients need monitoring.
Topics
Surgery
Monitoring
Research
Jargon explained
post-operative recurrence
colonoscopy
step-up
resection
New England Journal of Medicine
Study
May 2023
Patients and professionals
Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.
Topics
Medicines
Immunosuppressants
Research
Jargon explained
JAK inhibitor
small molecule
induction
maintenance
herpes zoster
endoscopic response
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
European Crohn's and Colitis Organisation (J Crohns Colitis)
Guideline
Oct 2024
For professionals
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics
Medicines
Biologics and newer medicines
Immunosuppressants
Around the bottom (perianal)
Jargon explained
biologic
immunomodulator
induction
maintenance
de-escalation
perianal fistula
GRADE
NICE
Guideline
Jul 2017
For professionals
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics
Biologics and newer medicines
Medicines
Jargon explained
interleukin inhibitor
TNF-alpha inhibitor
biological therapy